144 ·Filed Apr 13, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001964306-26-000201
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, small-scale disposition consistent with prior months' activity and not indicative of material concern. Traders should monitor for any acceleration in volume or changes in tone from management, but no immediate reaction is warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
MLYS ▲ +6.00% at T+60d
NEUTRAL call ✓ call won +6.00% · α vs SPY -2.52% · entry $27.32 → $28.96
Entry anchored
Apr 13, 03:59 PM ET
via exchange tick
T+1d
+11.35%
call +11.35% · α +10.57%
$30.42
settled 6mo ago
T+5d
+5.34%
call +5.34% · α +3.95%
$28.78
settled 6mo ago
T+20d
+8.82%
call +8.82% · α +2.53%
$29.73
settled 5mo ago
T+60d
+6.00%
call +6.00% · α -2.52%
$28.96
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

David Rodman, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell up to 14,058 shares of common stock, following a series of prior cashless exercises of stock options. This proposed sale is part of an ongoing pattern of insider transactions over the past several months.

Key Facts

  • David Rodman, an officer, filed Form 144 to sell up to 14,058 shares.
  • The shares are from a broker-assisted cashless exercise of employee stock options on April 13, 2026.
  • Rodman has conducted multiple similar transactions between January and April 2026, totaling over 77,000 shares sold.
  • No unusual timing relative to earnings or major catalysts is indicated.
  • Market cap is $2.2B; this sale represents a negligible portion of outstanding shares.

Financial Impact

Approximately $370,000 at recent prices (based on prior April 14 sale of 11,367 shares for $370,645), representing less than 0.1% of market cap.

insider ownershipshare countpotential dilution

Risk Factors

  • Perception of insider selling if aggregated with prior transactions
  • Potential downward pressure if sale is executed rapidly

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001964306-26-000201
Document: 0001964306-26-000201-index.html0001964306-26-000201
Document: 0001964306-26-000201.txt0001964306-26-000201
22 reports for MLYS
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access